THERAPEUTIC Pipeline

See our preclinical pipeline, including assets available to license. Licensing models can range from straight-out licensing to ongoing joint research.

Preclinical Pipeline ​

Target



Indication



Modality



Discovery



Optimization



Preclinical



License Status

Follow links to learn more

CLDN6

ovarian, endometrial

CD3 bispecific

Undisclosed

oncology

Undisclosed

CLDN18.2

gastric, pancreatic

Cell Therapy

CLDN18.2

solid tumors

Antibody–Drug Conjugate

Undisclosed

GPRC5D

multiple myeloma

CD3 bispecific

CCR8

immuno-oncology

Treg depletion

CLDN6

ovarian, endometrial

CD3 bispecific

Preclinical

Undisclosed

oncology

Undisclosed

Preclinical

CLDN18.2

gastric, pancreatic

Cell Therapy

Preclinical

CLDN18.2

solid tumors

Antibody–Drug Conjugate

Preclinical

Undisclosed

GPR5CD

multiple myeloma

CD3 bispecific

Preclinical

CCR8

immuno-oncology

Treg depletion

Optimization

Additional assets available for licensing: GLUT4 (metabolic), P2X3 (pain), P2X7 (immunity). Assets for additional undisclosed targets are in the discovery phase.

All antibody assets are exclusively owned by Integral Molecular and were discovered using our MPS Antibody Discovery platform.

Assets Available to License

We have monoclonal antibody assets available against the following targets. Follow the links to learn more:

  • CLDN18.2 x CD3 T cell engager for gastric and pancreatic cancer
  • GPCR5D x CD3 T cell engager for multiple myeloma
  • CCR8 for immuno-oncology
  • P2X3 for chronic cough and chronic pain
  • P2X7 for autoimmune conditions
  • GLUT4 for metabolic conditions
Integral is open to, and has concluded, a variety of licensing models, from straight-out licensing to ongoing joint research. We have flexibility to adjust to what works best for both parties.

The Integral Advantage: Best-in-class MAbs ​

Integral Molecular’s Antibody Discovery platform features immunization with native antigen and chickens as a divergent immunization host. These technologies deliver preclinical leads.
We’ve developed antibodies against certain targets because they’re generally regarded as promising. And we’re not the only ones to have done so. But there are a few reasons to think ours are better than the rest. Learn more about our industry-leading MPS Antibody Discovery Platform

“Integral Molecular have been outstanding partners in enabling us to advance our lead molecule CTIM-76 towards IND. They developed an antibody with unrivaled selectivity for CLDN6, an absolute requirement for safely and effectively targeting solid tumors.”

Therapeutic Asset Partners

Learn more about our current partnerships:

More Ways to Work Together: Explore our Related Technologies ​

MAb Discovery Partnerships

You have a promising biotherapeutic target, but you need support in developing a therapeutic against it.

We can help. From custom antigen design to delivery of preclinical leads ready for IND-enabling studies, we’re your partner.

Our industry-leading antibody discovery platform has a 95%+ success rate generating MAbs against even the most challenging membrane protein targets.

Learn more about our MPS Antibody Discovery Platform

Integral Molecular's MAb Discovery Partnerships

Target Discovery Partnerships

Discover novel therapeutic targets using our Membrane Proteome Array™ (MPA) platform.

The MPA has 6,000 human membrane proteins expressed on unfixed human cells. It is not only the leading solution for antibody specificity profiling, it also identifies potential new targets through functional assays.

Learn more about our MPA Platform

Integral Molecular's Target Discovery Partnerships

Ready To Get Started?

Contact us to discuss licensing therapeutic assets or initiating a discovery partnership.

Or call (215) 966-6061